Contributor Page
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Email  |  Website  |  Articles
Contact Details
Tel: +1 202 4084000
Fax: +1 202 4084400
901 New York Avenue, NW
Washington, DC
United States
By Stacey Lewis, Thomas Irving
25. (new) A pharmaceutical composition comprising a therapeutic agent effective to reduce the amount of active hsp27 in cancerous cells exposed to the therapeutic agent, and a pharmaceutically...
By Andrew Q. Leba, Shana Cyr
On September 4, 2018, the FDA issued final guidance on Physiologically Based Pharmacokinetic Analyses — Format and Content.
By Sanam Habib, Hazel Ford
In most jurisdictions, the amount of time spent in patent prosecution depends on the number of rounds of examination and the turnaround speed of the respective examining patent office.
By Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Starting in October 2018, there will be authentication changes coming for EFS-Web and PAIR at the USPTO.
By Guang-Yu Zhu, Margaret Esquenet, Naresh Kilaru
On August 16, 2018, a district judge in the Southern District of New York held that the creation of a program that allows players to cheat when they play a video game infringes the copyright...
By Frank Decosta, Aliza G. Carrano, Jack Li
We are in the midst of an artificial intelligence boom.
By Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
When arguing before the Federal Circuit, three lights on the podium serve as timers.
By Michael Flibbert, Megan Leinen Johns
Having a promising drug candidate in clinical trials can be an exciting time for a pharmaceutical company.
By Pejmon Pashai, Samhitha Muralidhar
In Luminara Worldwide, LLC v. Iancu, Nos. 17-1629, 17-1631, 17-1633 (Fed. Cir. Aug. 16, 2018), the Federal Circuit vacated the Board's determination that IPR petitioner Liown Electronics Co., Ltd. ...
By Daniel Klodowski, David Seastrunk, Michael R Galgano
The Patent Trial and Appeal Board issued 51 IPR and CBM Final Written Decisions in July, including decisions following remands from the Federal Circuit, cancelling 617 (79%) instituted claims while declining to cancel 143 (18.31%) instituted claims.
By Jessica Marks, Jeffrey Smyth
Engineered natural products, like lab-grown meat and synthetic milks, are on the cutting edge of food science.
By Bonnie Fletcher Price Ph.D., Kara Specht
In Click-to-Call Technologies, LP v. Ingenio, Inc. the en banc Federal Circuit addressed for the first time whether a petition was time barred under 35 U.S.C. § 315(b) where a previously-filed complaint was voluntarily dismissed.
By Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
For information regarding the Patent Application Locating and Monitoring database (PALM) outage that occurred August 15-23, 2018,
By Nate Ngerebara
In Ericsson Inc. v. Intellectual Ventures I LLC, No. 2017-1521 (Fed. Cir. Aug. 27, 2018), Ericsson appealed a PTAB
By Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
In addition to the standard format requirements of the PCT, applicants may also prepare applications in accordance with the Common Application Format
Contributor's Topics